Tampilkan postingan dengan label Mylan. Tampilkan semua postingan
Tampilkan postingan dengan label Mylan. Tampilkan semua postingan

Rabu, 29 Maret 2017

New EpiPen alternative for $4500!


Today’s Managing Health Care Costs Number is $4500



It seems like eons ago that we were arguing over EpiPen – an autoinjector that delivers a dirt-cheap generic medication that can save the life of someone who has an allergic reaction.  The drug was purchased by Mylan pharmaceuticals which progressively raised its price from $100 to $750 – and faced massive public outcry. 

Mylan’s CEO (the daughter of WV Senator Joe Manchin (D)) was subjected to Congressional hearings, and the company lowered the price (from $750 to $600) and introduced a generic version for half the price (which undersold another generic)

One interesting sidenote was that there had been an EpiPen competitor, Auvi-Q, produced by Sanofi, which gave audio instructions for injection. This had been priced competitivelywith EpiPen when it was introduced in 2013 (each was a bit shy of $250 for two doses) - but had been removed from the market due to production issues.

Good news.  Auvi-Q is back!

Not so good news.  Auvi-Q is priced at $4500 for two doses.

WHAT? 

It’s getting hard to summon outrage about pharmaceutical prices (and a lot else).  Why should a delivery system that was priced at $250 in 2013 be marketed for $4500 in 2017?  Obviously, when it comes to pricing there is no shame – the company selling this also sells Evzio, an autoinjector for naloxone  to reverse narcotic overdose for $4500

EpiPen Google searches 


Senin, 19 September 2016

Buying researchers is cheap.


Today’s Managing Health Care Costs Number is $6500




Stanton Glantz is the UCLA law professor who broke open the “tobacco papers” case, showing that “big tobacco” had suppressed information about the addictiveness and medical harm caused by cigarettes. Glantz and colleagues have a paper in JAMA Internal Medicine last week using archived documents from the Sugar Research Foundation, “big sugar,” showing that it purchased the services of Harvard researchers to put their fingers on the scale about whether sugar or fat is worse in our diets.   This led to the world of low fat everything – and nutritional landmines like “Snackwell” cookies that were devoid of fat (and taste) but filled with extra carbohydrates.

Big Sugar paid two Harvard School of Public Health (!) researchers $6500 in 1967, the equivalent of about $50,000 in today’s dollars.  In exchange, the researchers wrote a literature review published in 1967 in the New England Journal of Medicine which overstated the dangers of fat, and dismissed research that showed the danger of carbohydrates.  One of the researchers went on to help develop the food pyramid – which has been used to create the model diet for a generation.

It’s stunning how little it cost to purchase this influence.   The good news is that procedures at academic institutions and at top tier journals have improved substantially.  Authors must declare any potential conflicts, and peer review has improved.  Even so, this is deeply distressing.

This isn’t the only story of how little it takes to purchase opinions that can be published in peer reviewed journals.  The New York Times reported today that Mylan Pharmaceuticals paid ghostwriters to pen an editorial promoting making EpiPen a “preventive” medicine – which would mean that consumers would have no copayment.  A family medicine physician (who is also a paid consultant of Mylan) is listed as the author.   

Mylan also paid a total  about a quarter of a million dollars to ‘patient advocacy’ groups that are advocating to make EpiPen a preventive medication. That’s the equivalent of the revenue from under 400 prescriptions.   They might not prevail – but the price of a purchasing influence remains very small indeed!

Jumat, 02 September 2016

Because they can!


Today’s Managing Health Care Costs Number is $5.4 million

 Mylan Share Price 



Gretchen Morgenstern’s weekend “Fair Game” column is posted on the NYT website today – it reviews the implications of Mylan’s price increases for EpiPen on executive compensation.

Mylan put in place a special stock grant in 2014 which will be worth over $13 million to its CEO if the company meets its earnings and stock price goals – and could be worth far more. EpiPen’s price increases have been critical to achieving higher earnings and share price.

A company spokesman denied that EpiPen could have a big impact on the stock grant:

Mylan has a large and diverse business, with more than 2,700 products sold in 165 countries and 600 products sold in the U.S. alone. The targets set forth in the one-time special program were not and are not practically achievable based on pricing of any single product.

Not true.  EpiPen represents $1 billion in revenue (of total $9.5 in revenue).   Given that epinephrine costs only a few pennies and all the technology in the injectors is from the 1980s – virtually all EpiPen sales represent gross margin.  The drug needs little marketing – so margin contribution for each unit sold is the vast majority of sales revenue.  Mylan’s net income was $1.46b (2015), $1.34B (2014), and 1.16B(2013) – so EpiPen profits made up a healthy portion of this. 

It’s interesting to note that Mylan’s share priceand EpiPen price increases track very closely.  (Mylan is down about 9% in the last month – which does not show up well on the graph above).
Source

US pharmaceutical companies raise prices because they can -and raising prices absent competition is the best way to raise income, share price, and executive compensation.   Barring government price setting, common in the developed world but anathema here, we will need more competition -and government action to spur such competition.